Abstract Coronavirus disease of 2019 (COVID-19) is the respiratory viral infection caused by
the coronavirus SARS-CoV2 (Severe Acute Respiratory Syndrome Coronavirus 2). Despite …

Background The primary manifestation of coronavirus disease 2019 (COVID‐19) is
respiratory insufficiency that can also be related to diffuse pulmonary microthrombosis and …

Background Hypercoagulability may contribute to COVID‐19 pathogenicity. The role of
anticoagulation (AC) at therapeutic (tAC) or prophylactic doses (pAC) is unclear. Objectives …

Abstract Introduction The Italian Society of Anti-Infective Therapy (SITA) and the Italian
Society of Pulmonology (SIP) constituted an expert panel for developing evidence-based …

Introduction Although patients with severe COVID-19 are known to be at high risk of
developing thrombotic events, the effects of anticoagulation (AC) dose and duration on in …

Objective: Unusual clinical course Background: Coronavirus disease 2019 (COVID-19)
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) primarily affects …

Background: The use of anticoagulants has been endorsed by different hematological
societies as coagulation abnormalities are key features of COVID-19 patients. This …

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has become a global health concern. Three years …

Background. Most evidence regarding anticoagulation and COVID‐19 refers to the
hospitalization setting, but the role of oral anticoagulation (OAC) before hospital admission …

The spread of the COVID-19 disease has had significant social and economic impacts all
over the world. Numerous measures such as school closures, social distancing, and travel …